AstraZeneca plc (LSE:AZN) (STO:AZN) (NYSE:AZN) said on Saturday that clinical trials for the potential COVID-19 vaccine AZD1222 have resumed in the UK after clearance from safety authorities.
The investigational vaccine was developed by the University of Oxford and its spin-out company, Vaccitech. Trials were paused on 6 September after a report of dangerous side effects. However, the study participant who suffered the adverse effects had reportedly been suffering neurological symptoms associated with a rare spinal inflammatory disorder called transverse myelitis, City A.M. reported.
The UK's Medicines Health Regulatory Authority (MHRA) has now confirmed that it is safe to resume the trials.
AstraZeneca has entered into agreements to supply almost three billion doses of the vaccine to governments across the world.
CStone announces Phase I CS2009 data at ESMO 2025
Autonomix Medical secures new US patent to expand precision nerve-targeted therapies
Oxford BioDynamics and UEA develop 96% accurate blood test for Chronic Fatigue Syndrome
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Celltrion launches AVTOZMA IV in the United States following FDA approval
Novartis to launch US direct-to-patient platform for Cosentyx
Vascarta completes VAS-101 osteoarthritis clinical trial
Sen-Jam Pharmaceutical and KVK Tech complete final development deliverables for SJP-002C
OSE Immunotherapeutics forms strategic alliance with Inserm Transfert and Nantes University